Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Thompson

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
BJU International|August 23, 2018
MRI improves active surveillance of prostate cancer however biopsy is still crucialJames E Thompson, Phillip D Stricker
The Journal of Urology|June 27, 2020
Editorial CommentJames E Thompson, Phillip D Stricker
Blood|September 10, 2005
mTOR regulates cell survival after etoposide treatment in primary AML cellsQing Xu, James E Thompson, Martin Carroll
Journal of Clinical Apheresis|October 16, 2002
Use of plasma exchange, steroids, and anticoagulation in a patient with multiple arterial thromboses and IgM anticardiolipin antibodiesBruce S Sachais, James E Thompson, Frank J Strobl
Cancer|April 8, 2011
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectivesHun J Lee, James E Thompson, Eunice S Wang, et al.
Archives of Biochemistry and Biophysics|February 1, 2003
Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptideRuixiu Wang, Patrick R Griffin, Eliza C Small, et al.
The Medical Journal of Australia|October 24, 2007
Medical students, medical schools and international healthGregory J Fox, James E Thompson, Victor C Bourke, et al.
BJU International|November 15, 2019
Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatmentAlexandar Blazevski, Matthijs J Scheltema, Amer Amin, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-onesSwaminathan R Natarajan, David D Wisnoski, James E Thompson, et al.
Transfusion|January 19, 2016
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomibPriyank P Patel, Joanne Becker, Craig Freyer, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
BJU International|August 23, 2018
MRI improves active surveillance of prostate cancer however biopsy is still crucialJames E Thompson, Phillip D Stricker
The Journal of Urology|June 27, 2020
Editorial CommentJames E Thompson, Phillip D Stricker
Blood|September 10, 2005
mTOR regulates cell survival after etoposide treatment in primary AML cellsQing Xu, James E Thompson, Martin Carroll
Journal of Clinical Apheresis|October 16, 2002
Use of plasma exchange, steroids, and anticoagulation in a patient with multiple arterial thromboses and IgM anticardiolipin antibodiesBruce S Sachais, James E Thompson, Frank J Strobl
Cancer|April 8, 2011
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectivesHun J Lee, James E Thompson, Eunice S Wang, et al.
Archives of Biochemistry and Biophysics|February 1, 2003
Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptideRuixiu Wang, Patrick R Griffin, Eliza C Small, et al.
The Medical Journal of Australia|October 24, 2007
Medical students, medical schools and international healthGregory J Fox, James E Thompson, Victor C Bourke, et al.
BJU International|November 15, 2019
Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatmentAlexandar Blazevski, Matthijs J Scheltema, Amer Amin, et al.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-onesSwaminathan R Natarajan, David D Wisnoski, James E Thompson, et al.
Transfusion|January 19, 2016
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomibPriyank P Patel, Joanne Becker, Craig Freyer, et al.
Pageof 10